Skip to main content

Table 2 Clinical characteristics of post-COVID-19 syndrome

From: Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19

  N = 29
Symptoms—n (%)  
 Fatigue 25 (86%)
 Muscle pain 18 (62%)
 Dyspnea 14 (48%)
 Inappropriate sinus tachycardia 9 (31%)
 Low-grade fever 9 (31%)
Functional status  
 Grade 0 0 (0%)
 Grade I—n (%) 7 (24%)
 Grade II—n (%) 8 (27.5%)
 Grade III—n (%) 5 (17.2%)
 Grade IV—n (%) 9 (31%)
Median number of days until evaluation days (IQR) 57 (42–71)
Median number of days to extra-respiratory positive RT- PCR (IQR) 55 (39–67)
SARS-CoV-2 IgG tests—n (%) 25 (86%)
Hemoglobin (g/dL)—median (IQR) 14.3 (13.2–15)
Lymphocyte count (× 10E3/µl)—median (IQR) 1.4 (1.2–1.7)
Platelet count (× 10E3/µL)—median (IQR) 202 (184–238)
Serum creatinine (mg/dL)—median (IQR) 0.72 (0.63–0.82)
Alanin aminotransferase (U/L)—median (IQR) 24 (20–39.5)
  > 40 U/L—n (%) 7 (25%)
  ≤ 40 U/L—n (%) 21 (75%)
Ferritin (µg/L)—median (IQR) 100 (38.5–204)
  > 205 (µg/L)—n (%) 7 (25%)
  ≤ 205 (µg/L)—n (%) 21 (75%)
Positive SARS-CoV-2 RT-PCR  
 Plasma—n (%) 13 (44.8%)
 Stool—n (%) 5 (17.2%)
 Urine—n (%) 4 (13.7%)
 At least one positive result—n (%) 15 (51.7%)
 Two positive results—n (%) 5 (17,2%)
 Three positive results—n (%) 2 (6.8%)
  1. n  number, IQR  interquartile range